Global Antibiotic R&D Partnership (GARDP) Scientific Consultation

29 February, 2016
Institut Pasteur, Paris, France


Cover photo: © Swiss TPH
© Swiss TPH


A joint WHO/DNDi initiative incubated by DNDi in support of the Global Action Plan for Antimicrobial Resistance

Developing new antibiotic treatments, promoting responsible use, and ensuring access for all

Scientific Consultation Summary



Welcome Remarks
Christian Bréchot, President Institut Pasteur
Introduction, GARDP Incubation & DNDi’s Role
Bernard Pécoul, Executive Director, DNDi
Update on WHO Global Action Plan on Antimicrobial Resistance
Liz Tayler, WHO AMR Secretariat
Key Criteria, Milestones, and Sourcing of Initial Short and Medium-Term GARDP Projects
Jean-Pierre Paccaud, Business Development Director, DNDi
Embedding Conservation and Access into Each Project from the Start
Manica Balasegaram, Executive Director, MSF Access Campaign
Bringing Diagnostics into the Equation
Bill Rodriguez, Chief Medical Officer, FIND (via VC) Anti-Microbial Resistance: Landscape Analysis of the State of AMR Testing Technologies


Combination Issues for Existing Antibiotics

Overview of Antibiotic Drug Combination Issues
Anthony Coates, Medical Microbiology Institute, St George’s, University of London
Antibiotic Resistance Breakers for Use in Combinations
David Brown, Antibiotics Research UK (ANTRUK)


Proposed Project Presentations & Discussion


Chairs: Liz Tayler and Manica Balasegaram

Open Research Platform for Antibiotic Combinations & Open Platform for Improving Usage of Old Antibiotics (dosing regimens, indications)
Ursula Theuretzbacher, Center for Anti-infective Agents Vienna
– Angela Huttner, University Hospitals of Geneva
Sanofi’s Antibiotic Drug Combinations and Formulations Work
Laurent Fraisse, Sanofi
– Michael Mourez, Sanofi
– Nathalie Moniot-Ville, Sanofi
Oral Tebipenem for Extended‐Spectrum Beta‐Lactamase (ESBL)‐producing Enterobacteriaceae + New Polymyxin Formulations
Visanu Thamlikitkul, Mahidol University
Jutta Heim, Evolva & Jo Larsen, BARDA
Kamini Walia, Indian Council of Medical Research
Addressing Antibiotic Treatment of Neonatal & Infant SBI in the Context of High MDRGM
Mike Sharland, NHS UK / Paul Heath, St. Georges Vaccine Institute
New Formulations of Amoxicillin/Clavulanic Acid and Challenges of Heat Stability
– Marie-Claude Bottineau, MSF
– Emmanuel Baron, Epicentre
Jean-René Kiechel, DNDi
Astellas Drug Formulation Overview
Hasegawa Yu, Astellas Pharma Inc.
Zoliflodacin for the Management of Uncomplicated Gonorrhoea
Robin Isaacs, Entasis Therapeutics (via VC)
Enteric Fever
Hellen Gelband, Center for Disease Dynamics, Economics & Policy
– Chris Parry, London School of Hygiene and Tropical Medicine and Nagasaki University (via VC)
– Buddha Basnyat, Oxford University Clinical Research Unit, Nepal (via VC)
Targeting the Cell Wall Elongation Machinery
Ivo Gomperts Boneca, Institut Pasteur


Full Programme
GARDP Project Proposal Template
GARDP Initial Project Proposals


Find out more about the Global Antibiotic Research and Development Partnership (GARDP)